Stemgent
Encyclopedia
Stemgent is an American privately funded biotech company focused on providing reagents and technology developed by some of the world's leading stem cell scientists. Founded in 2008, Stemgent has two fully operational facilities in both San Diego, California and Cambridge, Massachusetts. Stemgent currently has 40 employees.
The company is designed to serve researchers who study stem cell biology and regenerative medicine and those who use cells derived from stem cells as tools to advance their understanding of major diseases.
April 2008: San Diego, CA facility opens
Stemgent ranked as one of the top 25 up and coming biotech companies.
In April 2010, Stemgent and Pfizer sign collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community. May 2010, Stemgent and Miltenyi Biotec announced a strategic collaboration for co-development and commercialization of stem cell research products. Milltenyi Biotech supports worldwide marketing and sales of Stemgent’s current product portfolio.
In September 2010, Stemgent held the first commercially available iPS training course at the National Institute of Health facility
. In the wake of the courses' success, Stemgent planned three additional courses for the 2010 calendar year. On December 7–10th Stemgent’s first human iPS training course will be held at the San Diego facility to a full class, including students from Japan and Thailand.
In January 2011, Stemgent launched "StemgentTv" on YouTube. Over the course of 3-4 months, Stemgent added 15 video protocols to support current products and helpful user techniques. In addition, in June 2011 Stemgent released an exclusive interview with Rudolf Jaensich, who discussed the future cellular reprogramming.
In August 2011 Stemgent held the first mRNA reprogramming training course at their San Diego facility. In the wake it's success, the mRNA course was added to the list training courses held year round at Stemgent. In December 2011 in collaboration with the University of Sheffield Centre for Stem Cell Biology, Stemgent held their first international training course in mRNA reprogramming.
November 2011: Stemgent is nominated for a Life Science Industry Award (LSIA) in the "Breakthrough Product for Stem Cell Research" category.
The company is designed to serve researchers who study stem cell biology and regenerative medicine and those who use cells derived from stem cells as tools to advance their understanding of major diseases.
2008 Milestones
February 2008: First Stemgent office opens in Cambridge, MAApril 2008: San Diego, CA facility opens
2009 Milestones
November 2009 – Sigma Aldrich and Stemgent signed a worldwide distribution agreement to offer lentivirus-based delivery systems for the generation of induced pluripotent stem cells (iPSC).Stemgent ranked as one of the top 25 up and coming biotech companies.
2010 Milestones
In early 2010, Stemgent launched custom cell line generation services providing companies in iPS cell line generation engineer reporter cell lines, and characterized pluripotent iPS or ES cells. In March 2010, Stemgent launched Ubiquigent Ltd, a new biotechnology company based in Dundee, Scotland. Ubiquigent produces technology that focuses on the biology of the ubiquitin protesome pathway (UPP). Ubiquigent is housed by the Scottish Institute for ceLL Signalling (SCILLS) at the University of Dundee and is co-founded by Professor Sir Philip Cohen.In April 2010, Stemgent and Pfizer sign collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community. May 2010, Stemgent and Miltenyi Biotec announced a strategic collaboration for co-development and commercialization of stem cell research products. Milltenyi Biotech supports worldwide marketing and sales of Stemgent’s current product portfolio.
In September 2010, Stemgent held the first commercially available iPS training course at the National Institute of Health facility
National Institutes of Health
The National Institutes of Health are an agency of the United States Department of Health and Human Services and are the primary agency of the United States government responsible for biomedical and health-related research. Its science and engineering counterpart is the National Science Foundation...
. In the wake of the courses' success, Stemgent planned three additional courses for the 2010 calendar year. On December 7–10th Stemgent’s first human iPS training course will be held at the San Diego facility to a full class, including students from Japan and Thailand.
2011 Milestones
In 2011, Stemgent launched their mRNA reprogramming product line. The mRNA reprogramming factors set was first available in the March 2011, followed by the launch of the Pluriton Reprogramming medium in June 2011 . In October 2011, Stemgent launched the reprogramming kit. The kit components are qualified together for reprogramming and consists of the reprogramming factors set, Pluriton Reprogramming medium, and B18R human recombinant protein (credit *http://us.ebioscience.com/ EBioscience, Inc.)In January 2011, Stemgent launched "StemgentTv" on YouTube. Over the course of 3-4 months, Stemgent added 15 video protocols to support current products and helpful user techniques. In addition, in June 2011 Stemgent released an exclusive interview with Rudolf Jaensich, who discussed the future cellular reprogramming.
In August 2011 Stemgent held the first mRNA reprogramming training course at their San Diego facility. In the wake it's success, the mRNA course was added to the list training courses held year round at Stemgent. In December 2011 in collaboration with the University of Sheffield Centre for Stem Cell Biology, Stemgent held their first international training course in mRNA reprogramming.
November 2011: Stemgent is nominated for a Life Science Industry Award (LSIA) in the "Breakthrough Product for Stem Cell Research" category.
Focus
Stemgent currently sells over 220 products for stem cell research. Stemgent products are developed with the aim to be both cutting edge and novel while also timely and easy to use. Many Stemgent products are provided in kit form to build complete experiments.Key Products
- Stemedia NutriStem XF/FF Culture Medium: xeno free/feeder free, low growth factor human embryonic stem (ES) and induced plutipotent stem (iPS) cell culture medium that enables maintenance and expansion of pluripotent stem cells
- Stemedia WIT-P Culture Medium:for the robust culture of human breast primary epithelial cells
- Stemedia WIT-I Culture Medium: for the robust culture of human immortalized mammary epithelial cells
- Stemedia WIT-T Culture Medium: for the culture of transformed human mammary epithelial cells
- Stemfect 2.0-mESC DNA Transfection Reagent:polymer base transfection reagent for in vitro DNA transfection of mouse embryonic cells
- Stemfect DNA Plasmid Transfection Polymer: polymer specifically designed to transfect stem cells
- Stemfect RNA Transfection Kit: a proprietary mixture of lipid components is specifically designed for in vitro RNA transfection.
- Stemgent mRNA Reprogramming Factors Set: hOKSML: contains mRNA encoding Oct4, Klf4, Sox2, c-Myc, Lin-28, and nuclear GFP (nGFP).
- Stemgent mRNA reprogramming kit : Full mRNA reprogramming kit which include the factors set, Pluriton Reprogramming medium, and B18R human recombinant protein (credit *http://us.ebioscience.com/ EBioscience, Inc.)
- Pluriton Reprogramming Medium :defined, xeno-free medium optimized for mRNA based cellular reprogramming of human cells.
Scientific Advisory Board
- Daniel Anderson, Ph.D
- MIT (Massachusetts Institute of Technology)
- Robert Langer, Sc.D
- MIT (Massachusetts Institute of Technology)
- Hongkui Deng, Ph.D
- Peking UniversityPeking UniversityPeking University , colloquially known in Chinese as Beida , is a major research university located in Beijing, China, and a member of the C9 League. It is the first established modern national university of China. It was founded as Imperial University of Peking in 1898 as a replacement of the...
- Douglas A. Melton, Ph.DDouglas MeltonDouglas A. Melton is the Xander University Professor at Harvard University, and an investigator at the Howard Hughes Medical Institute. Additionally, Dr. Melton serves as the co-director of the Harvard Stem Cell Institute and the co-chair of the Harvard University Department of Stem Cell and...
- Howard Hughes Medical InstituteHoward Hughes Medical InstituteHoward Hughes Medical Institute is a United States non-profit medical research organization based in Chevy Chase, Maryland. It was founded by the American businessman Howard Hughes in 1953. It is one of the largest private funding organizations for biological and medical research in the United...
- Elaine Fuchs, Ph.DElaine FuchsElaine V. Fuchs is an American cell biologist, famous for her work on the biology and molecular mechanisms of mammalian skin and skin diseases, and has led the modernization of dermatology. Fuchs also pioneered reverse genetics approaches, which assess protein function first and then assesses its...
- The Rockefeller University
- Jeffrey Karp, Ph.D
- Brigham and Women's HospitalBrigham and Women's HospitalBrigham and Women's Hospital is the largest hospital of the Longwood Medical and Academic Area in Boston, Massachusetts. It is directly adjacent to Harvard Medical School of which it is the second largest teaching affiliate with 793 beds...
- Thomas Roberts, Ph.D
- Dana Farber Cancer Institute
- Robert Weinberg, Ph.D
- Whitehead InstituteWhitehead InstituteFounded in 1982, the Whitehead Institute for Biomedical Research is a non-profit research and teaching institution located in Cambridge, Massachusetts, USA....
- Alan Colman, Ph.D
- Singapore Stem Cell Consortium
- Sheng Ding, Ph.D
- Scripps Research Institute
- Rudolf JaenischRudolf JaenischRudolf Jaenisch is a biologist at MIT. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating transgenic mice to study cancer and neurological diseases....
, Ph.D
- Whitehead InstituteWhitehead InstituteFounded in 1982, the Whitehead Institute for Biomedical Research is a non-profit research and teaching institution located in Cambridge, Massachusetts, USA....
- Gordon Keller, Ph.D
- Ontario Cancer InstituteOntario Cancer InstituteThe Ontario Cancer Institute is the research division of Princess Margaret Hospital, part of the University Health Network of the University of Toronto Faculty of Medicine. As Canada's first dedicated cancer hospital, it opened officially and began to receive patients in 1958, although its...
- Ruth McKernan, Ph.D
- Pfizer Regenerative Medicine
- Roy Ogle, Ph.D
- University of VirginiaUniversity of VirginiaThe University of Virginia is a public research university located in Charlottesville, Virginia, United States, founded by Thomas Jefferson...
- Lee Rubin, Ph.D
- Harvard Stem Cell Research Institute
- Leonard Zon, Ph.D
- Children's Hospital BostonChildren's Hospital BostonChildren's Hospital Boston is a 396-licensed bed children's hospital in the Longwood Medical and Academic Area of Boston, Massachusetts.At 300 Longwood Avenue, Children's is adjacent both to its teaching affiliate, Harvard Medical School, and to Dana-Farber Cancer Institute...